Search clinical trials for: Hormone sensitive

Total 55656 results

Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
University of Miami

Not yet recruiting

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer (OCEAN)

Prostate Cancer | Prostate Adenocarcinoma | Hormone Sensitive Prostate Cancer

United States
Peking University First Hospital

Not yet recruiting

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Prostate Adenocarcinoma
Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
Bayer

Not yet recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Non-metastatic Castration-resistant Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

Korea, Republic of
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Pedro Barata, MD, MSc
ESSA Pharma Inc.

Not yet recruiting

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

United States
RenJi Hospital

Recruiting

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer (CREATIVE)

Prostate Cancer

China
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Northwestern University
National Cancer Institute (NCI)

Recruiting

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Ellen Greenblatt
EMD Serono

Not yet recruiting

FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients

Fertility Preservation
West China Second University Hospital

Recruiting

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Ovarian Cancer

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Steno Diabetes Center Copenhagen

Recruiting

The ACCT2 Study Individuals With Type 2 Diabetes and Non-Western Backgrounds (ACCT2) (ACCT2)

Type 2 Diabetes

Denmark
Jianbin Bi

Not yet recruiting

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer (RASTOM)

Metastatic Hormone-Sensitive Prostate Cancer
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
University Hospital Padova

Recruiting

Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn (WHYSKI)

Hypertension | Essential Hypertension | Hyperaldosteronism | Aldosteronism | Conn Adenoma | Aldosterone Disorder | Aldosterone-producing Adenoma | Bilateral Adrenal Hyperplasia

Italy
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
Icahn School of Medicine at Mount Sinai

Not yet recruiting

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Ovarian Cancer | Malignant Neoplasm of Uterus

United States
Royal Marsden NHS Foundation Trust
Janssen, LP

Recruiting

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients (ADAPT-P)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United Kingdom
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer (DADOX)

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Japan
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

China
Lan Coffman
National Cancer Institute (NCI); MorphoSys AG

Recruiting

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

United States
Catherine Spina
Arcus Biosciences, Inc.

Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)

Oligometastatic Prostate Cancer

United States
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)

Metastatic Castrate-sensitive Prostate Cancer

United States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
Children's Hospital of Fudan University
Shanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital... and other collaborators

Not yet recruiting

Rituximab in the First Episode of Paediatric Nephrotic Syndrome

Steroid-Sensitive Nephrotic Syndrome

China
Assiut University

Not yet recruiting

Evaluation of Serum Pentraxin 3 and High Sensitive CRP in Female Patients With Gestational Diabetes Mellitus in Second Trimester of Pregnancy

Gestational Diabetes Mellitus in Second Trimester of Pregnancy
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Fudan University

Not yet recruiting

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment (CHAMPION)

Metastatic Prostate Cancer | Castration-Sensitive Prostate Cancer

China
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer (PERSIAN)

Oligometastatic Hormone Sensitive Prostate Cancer

Italy
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Recruiting

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United States
Jena University Hospital
Bayer

Recruiting

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Germany
Fondazione IRCCS Istituto Nazionale dei Tumori,...
European Institute of Oncology; ASST Santi Paolo e Carlo

Recruiting

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment (APPROACH)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Italy
Chongqing University Cancer Hospital

Recruiting

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Ovarian Cancer

China
UMC Utrecht

Recruiting

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide (PET-MaN-enza)

Prostate Cancer

Netherlands
Instituto Mexicano del Seguro Social
Instituto Nacional de Salud Publica, Mexico; Universidad Nacional Autonoma... and other collaborators

Recruiting

Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy (EA&DPN)

Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | Acupuncture | Diabetic Polyneuropathy | Electroacupuncture | Nerve Conduction

Mexico
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

Chemotherapy Effect | DNA Damage Repair Deficiency | Chemotherapeutic Toxicity | Hormone Sensitive Metastatic Prostate Cancer

China
ImmunoGen, Inc.
GOG Foundation

Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Czechia, Philippines, Israel, Belgium
Fudan University
BGI Tianjin

Recruiting

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer (EOC)

Ovarian Cancer

China
James J. Peters Veterans Affairs Medical Center

Not yet recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Metastatic Cancer | Neoplasm, Prostate

United States
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Not yet recruiting

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (t)

Epithelial Ovarian Cancer
Universitaire Ziekenhuizen KU Leuven

Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (SPARKLE)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate Cancer

Belgium
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene

Recruiting

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Prostate Cancer | Stage IV Prostate Cancer

United States

Search clinical trials for: Hormone sensitive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations